Of course, the ability of PAFAH1B3 to serve as a predictive marker for the efficacy of PD-1/PD-L1 inhibitors in HCC patients still needs to be conclusively confirmed in the cohort of HCC patients we recruited to receive PD-L1 or PD1 therapy. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.